Chemosensitization of HepG2 cells by suppression of NF-κB/p65 gene transcription with specific-siRNA

Figure 5 The viability of human HepG2 cells with doxorubicin after nuclear factor-κB/p65 siRNA transfection. A: The effects of doxorubicin on HepG2 cells by MTT assay during a 24 h period. All values are means of independent triplicate experiments. Dox, doxorubicin; B: Nuclear factor-κB (NF-κB)/ siRNA inhibition of NF-κB/p65 sensitized the HepG2 cells to doxorubicin, 1, control; 2, 0.5 μmol/L of doxorubicin for 48 h; 3, negtive siRNA for 24 h, then added 0.5 μmol/L of doxorubicin for another 24 h; 4, 100 nmol/L of NF-κB/p65 siRNA for 24 h, then added 0.5 μmol/L of doxorubicin for another 24 h. Data were derived from three independent experiments (n = 3).